{
    "abstract": "Atrial fibrillation (AF) is associated with an increased risk of hospital admission, but few data on reasons for hospitalization and on the role of anti-arrhythmic drugs are available.\nThe purpose of this study was to investigate the incidence rate and factors associated with all-cause, cardiovascular, and AF-related hospitalizations.\nProspective ongoing ATHERO-AF (Atherosclerosis in Atrial Fibrillation) cohort study enrolling AF patients on oral anticoagulants. Primary end points were all-cause, cardiovascular, and AF-related hospitalization, the latter defined as AF recurrences for paroxysmal AF and high-rate symptomatic AF episodes for persistent/permanent AF patients.\n2,782 patients were included (43.5% female; mean age was 74.6\u00a0\u00b1\u00a09.1\u00a0years). During a mean follow-up of 31\u00a0\u00b1\u00a026.8\u00a0months, 1,205 (12.1%/year) all-cause, 533 cardiac (5.7%/year), and 180 (2.0%/year) AF-related hospitalizations occurred. Predictors of AF-related hospitalizations were the use of flecainide/propafenone in both paroxysmal and persistent/permanent AF patients (HR: 1.861; 95%\u00a0CI: 1.116 to 3.101 and 1.947; 95%\u00a0CI: 1.069 to 3.548, respectively). Amiodarone (HR: 3.012; 95%\u00a0CI: 1.835-4.943), verapamil/diltiazem (HR: 2.067; 95%\u00a0CI: 1.117-3.825), and cancer (HR: 1.802; 95%\u00a0CI: 1.057-3.070) but not beta-blockers and digoxin were associated with an increased risk of AF-related hospitalizations in persistent/permanent AF patients.\nElderly AF patients frequently undergo hospitalizations for both cardiovascular and noncardiovascular causes. The use of anti-arrhythmic drugs was associated with an increased risk of AF-related hospitalization suggesting a scarce effect of these drugs in preventing AF episodes. Therefore, their use should be carefully considered and reserved for symptomatic patients with frequent AF recurrences.",
    "authors": [
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.\nDepartment of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy.",
            "firstname": "Danilo",
            "initials": "D",
            "lastname": "Menichelli"
        },
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.",
            "firstname": "Pasquale",
            "initials": "P",
            "lastname": "Pignatelli"
        },
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.",
            "firstname": "Tommaso",
            "initials": "T",
            "lastname": "Brogi"
        },
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.",
            "firstname": "Arianna",
            "initials": "A",
            "lastname": "Pannunzio"
        },
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.",
            "firstname": "Francesco",
            "initials": "F",
            "lastname": "Violi"
        },
        {
            "affiliation": "Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.\nDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.",
            "firstname": "Gregory Y H",
            "initials": "GYH",
            "lastname": "Lip"
        },
        {
            "affiliation": "Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.\nLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.",
            "firstname": "Daniele",
            "initials": "D",
            "lastname": "Pastori"
        },
        {
            "affiliation": null,
            "firstname": null,
            "initials": null,
            "lastname": null
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2024 The Authors.",
    "doi": "10.1016/j.jacadv.2024.101117\n10.1055/s-0043-1770724",
    "journal": "JACC. Advances",
    "keywords": [
        "amiodarone",
        "antiarrhythmic",
        "atrial fibrillation",
        "digoxin",
        "flecainide",
        "hospitalization"
    ],
    "methods": null,
    "publication_date": "2024-08-06",
    "pubmed_id": "39105112\n22782205\n29038167\n23355661\n33346822\n30659810\n37697684\n18326853\n21757483\n27174904\n33740910\n24766985\n33960309\n20103757\n37921006\n32586583\n27224469\n29438514\n28960189\n34773920\n34020488\n37369234\n37399842",
    "results": "2,782 patients were included (43.5% female; mean age was 74.6\u00a0\u00b1\u00a09.1\u00a0years). During a mean follow-up of 31\u00a0\u00b1\u00a026.8\u00a0months, 1,205 (12.1%/year) all-cause, 533 cardiac (5.7%/year), and 180 (2.0%/year) AF-related hospitalizations occurred. Predictors of AF-related hospitalizations were the use of flecainide/propafenone in both paroxysmal and persistent/permanent AF patients (HR: 1.861; 95%\u00a0CI: 1.116 to 3.101 and 1.947; 95%\u00a0CI: 1.069 to 3.548, respectively). Amiodarone (HR: 3.012; 95%\u00a0CI: 1.835-4.943), verapamil/diltiazem (HR: 2.067; 95%\u00a0CI: 1.117-3.825), and cancer (HR: 1.802; 95%\u00a0CI: 1.057-3.070) but not beta-blockers and digoxin were associated with an increased risk of AF-related hospitalizations in persistent/permanent AF patients.",
    "title": "Incidence of All-Cause, Cardiovascular, and Atrial Fibrillation-Related Hospitalizations: Focus on Antiarrhythmic Drugs.",
    "xml": "<Element 'PubmedArticle' at 0x788503fa7fb0>"
}